Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Breast Neoplasms · Breast Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 181 (planned)
- Started
- Feb 26, 2025
- Main results expected
- Aug 2, 2032
- Fully finished
- Aug 2, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Number of Participants Experiencing Dose-Limiting Toxicity (DLT)
Measured over: Up to 21 days
Part 1: Number of Participants with One or More Adverse Events (AEs)
Measured over: Up to approximately 36 months
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
Measured over: Up to approximately 12 months
Part 2: Objective Response Rate (ORR)
Measured over: Up to approximately 36 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06686394 · record last updated 2026-10-21 · checked 2026-11-09 15:47 UTC